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Abstract
The objective of this work was to study the distribu-
tion of apolipoprotein E (APOE) genotypes in a sam-
ple of the Portuguese population, and its association
with the dyslipidemias observed. Study participants
were healthy users of local Public Health Laboratories
in six regions of mainland Portugal (Porto, Vila Real,
Viseu, Lisboa, Portalegre and Faro). A total of 779
men and 1153 women aged 15–74 years agreed to
participate. Fasting lipid levels and APOE genotypes
were determined centrally at the National Institute of
Health in Lisboa. The frequency distribution of APOE
alleles was: ´2s5.3%, ´3s84.9% and ´4s9.8%. Dys-
lipidemias were present in 66.6% of men and 60.7%
of women. Comparison of APOE genotypes and rel-
ative allele frequencies showed that in dyslipidemic
compared to normolipidemic subjects, the ´4 allele
was more frequent in both sexes, although in a more
pronounced way in men than in women due to higher
frequencies of ´3/´4 and ´4/´4 genotypes. The known
association of the ´4 allele with high cholesterol lev-
els, the association of the ´2 allele with low choles-
terol levels, and the association of the ´2 allele with
high levels of triglycerides and low levels of high-den-
sity lipoprotein-cholesterol were confirmed in this
study.
Keywords: APOE genotypes; cardiovascular diseases;
dyslipidemias; Portuguese regions.
Introduction
The apolipopotein E (APOE) gene locus is polymor-
phic and three common alleles, ´2, ´3, ´4, are inher-
ited in a codominant way. These encode isoforms of
the corresponding plasma proteins, E2, E3, and E4,
which can occur in six different phenotypes. The E3/3
phenotype is the commonest in different populations.
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These isoforms differ by a single amino acid substi-
tution and, consequently, have different binding affin-
ities for the four known apoE receptors. Specific
literature on the complex biochemical aspects of the
mechanisms involved is abundant (1–3).
The isoforms are related to amino acid substitu-
tions in E2, E3, and E4 that influence their ionic bind-
ing to specific receptor domains and kinetics (4).
Through this principal mechanism, apoE influences
the metabolism of atherogenic lipoproteins – apoB-
containing lipoproteins – and the reverse cholesterol
transport (5).
Compared with ´3, the ´2 allele is frequently asso-
ciated with low levels of total and low-density lipo-
protein-cholesterol (LDL-C) and the opposite typically
occurs with the ´4 allele. Nevertheless, the ´2 allele
is also associated with a tendency towards higher tri-
glyceride levels (6). APOE genotypes may thus influ-
ence mean plasma lipid values and the frequency of
various types of dyslipidemias, which are considered
important risk factors for the development of athero-
sclerosis and cardiovascular diseases (CVD) (7, 8).
The Portuguese population is characterized by high
rates of dyslipidemias and CVD, but not much is
known about the influence of APOE genotypes on
these situations (9–12).
The aim of this work was to study the distribution
of APOE genotypes in the population of six regions of
mainland Portugal and to relate them to the dyslipi-
demias observed.
Materials and methods
Sampling locations and subjects
Six regions across mainland Portugal were selected as sam-
pling locations: Porto, Vila Real and Viseu in the north; Lis-
boa and Portalegre in the center; and Faro in the South.
Blood samples were collected from users of the six local
Public Health Laboratories attending for health control
checks, who were randomly invited to participate every day
during 6 months.
The sample population distribution was: 24.9% in Porto,
27.6% in Lisbon, the biggest cities, 12.8% in Vila Real, 12.7%
in Viseu, 11.7% in Portalegre and 10.3% in Faro, totaling 779
men and 1153 women, aged 15–74 years. None of them
reported taking hypolipidemic drugs or oral contraceptives.
All subjects gave their written informed consent to partici-
pate and the Ethics Committee at the National Institute of
Health (NIH) approved the study.
Blood samples
Blood samples were collected by venepuncture, with sub-
jects in a sitting position after overnight fasting. Two vacu-
tainer tubes were used, one with EDTA for DNA extraction
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Table 1 Lipid characteristics of normolipidemic and dyslipidemic participants.
Normolipidemic subjects Male Female p
ns260 (33.38%) ns453 (39.29%)
Age, years 38.7"17.6 37.5"14.5 NS
Cholesterol, mmol/L 4.08"0.58 4.20"0.55 -0.01
Triglycerides, mmol/L 0.96"0.29 0.95"0.32 NS
HDL-C, mmol/L 1.27"0.19 1.46"0.27 -0.001
LDL-C, mmol/L 2.39"0.52 2.33"0.50 NS
ApoA1, g/L 1.39"0.21 1.53"0.26 -0.001
ApoB, g/L 0.90"0.18 0.89"0.17 NS
Dyslipidemic subjects Male Female p
ns519 (66.62%) ns700 (60.71%)
Age, years 48.8"14.4 49.6"15.4 NS
Cholesterol, mmol/L 5.58"1.26 5.81"1.07 0.001
Triglycerides, mmol/L 2.10"1.41 1.62"0.91 -0.001
HDL-C, mmol/L 1.13"0.33 1.45"0.39 -0.001
LDL-C, mmol/L 3.57"1.13 3.66"0.98 NS
ApoA1, g/L 1.39"0.29 1.62"0.34 -0.001
ApoB, g/L 1.28"0.30 1.30"0.29 NS
Values are mean"SD. NS, not significant.
and the other for serum separation. Samples were trans-
ported at 48C, when possible by airmail, to the Central Clin-
ical Chemistry Laboratory at the NIH, where lipids were
immediately quantified and EDTA samples were stored at
y808C. APOE genotyping was performed within 1 month.
DNA extraction and APOE genotyping
DNA extraction was performed according to the method of
Miller et al. (13). APOE genotyping was performed by PCR
amplification and subsequent digestion with restriction
enzyme HhaI as described by Hixson and Vernier (14).
Lipid analysis
Serum total cholesterol, high-density lipoprotein-cholesterol
(HDL-C) and triglycerides were measured using an enzymatic
colorimetric method. Apoliproteins A1 and B were deter-
mined by immunoturbidimetry using a Hitachi 911 automat-
ed clinical chemistry analyzer (Boehringer Mannheim, Kobe,
Japan). The same manufacturer supplied the reagents. The
intra- and inter-assay coefficients of variation for these
assays were 2.6% and 2.5% for total cholesterol, 4.0% and
4.5% for HDL-C, 2.0% and 2.5% for triglycerides, 1.7% and
6.6% for apoA1, and 3.2% and 8.9% for apoB, respectively.
LDL-C was calculated according to the Friedwald-Fredrick-
son equation for individuals whose serum triglyceride levels
were lower than 4.54 mmol/L.
Different dyslipidemic types were defined based on total
cholesterol, LDL-C, HDL-C, and triglyceride levels according
to cut-off values specified by the American Expert Panel on
Detection, Evaluation and Treatment of High Blood Choles-
terol in adults (15).
Statistical analysis
Student’s t-test for independent samples, or the non-para-
metric Mann-Whitney U-test, when appropriate, was used
for comparing the mean values of age and lipid parameters.
The assumption of equality of variances was tested using
Levene’s test. A simple gene-counting method was used to
estimate allelic frequencies. Hardy-Weinberg equilibrium
and statistical comparisons between populations were per-
formed with a x2 test.
The association between APOE genotypes and blood lipid
levels was determined by computation of specific odds
ratios (ORs) for the association of each blood lipid with each
of the three APOE alleles (present vs. absent) in both men
and women. The different ORs were adjusted for the differ-
ent age structure of study subpopulations using logistic
regression.
Statistical analyses were performed using SPSS software
version 11.0 (SPSS Inc., Chicago, IL, USA) and STATA ver-
sion 8 for Windows (STATA Corporation, College Station,
TX, USA). p-Values less than 0.05 were considered statisti-
cally significant.
Results
Lipid results
Gender differences in blood lipid levels were
observed in normolipidemic subjects: women had
higher cholesterol than men, but HDL-C and apoA1
were lower in men than in women.
Dyslipidemic subjects, 66.6% men and 60.7% wom-
en, showed the same differences as normolipi-
demic participants: higher cholesterol in women, and
higher triglycerides, lower HDL-C and apoA1 in men
(Table 1).
Dyslipidemia characterized by hypercholesterole-
mia was more prevalent in women than in men. On
the other hand, isolated hypertriglyceridemia or in
association with low HDL-C was more frequent in
men.
Dyslipidemic subjects were on average 10 years
older than normolipidemics and this was taken into
account when calculating the ORs for the association
between APOE alleles and lipid concentrations,
adjusting for age using logistic regression methods.
Distribution of APOE genotypes
Table 2 shows the distribution of APOE genotypes in
Hardy-Weinberg equilibrium in all participating re-
gions. A borderline deviation was observed only
when APOE genotypes were considered together
(x2s6.01; ps0.049).
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Table 2 Frequency of APOE genotypes and alleles in six Portuguese regions.
Porto Vila Real Viseu Lisboa Portalegre Faro Total
Genotype
´2/´2 1 1 1 2 3 0 8 (0.4%)
´2/´3 35 25 20 49 18 15 162 (8.9%)
´2/´4 1 2 3 5 3 1 15 (0.8%)
´3/´3 381 169 154 361 134 126 1325 (72.4%)
´3/´4 69 34 36 90 31 34 294 (16.1%)
´4/´4 7 1 6 4 3 4 25 (1.4%)
Total 494 232 220 511 192 180 1829
x2 test 5.24 0.34 4.399 0.60 5.92 1.94 6.01
p 0.073 0.844 0.111 0.741 0.052 0.379 0.049
Allele
´2 0.038 0.058 0.060 0.057 0.070 0.045 0.053
´3 0.877 0.791 0.825 0.842 0.826 0.838 0.849
´4 0.085 0.151 0.115 0.101 0.104 0.117 0.098
Table 3 Mean values and standard deviation for lipids, apoA1, apoB and age, according to APOE genotype and sex.
Men Women
´2/´3 ´3/´3 ´3/´4 ´2/´3 ´3/´3 ´3/´4
Number 62 515 128 96 781 157
Total cholesterol, mmol/L 4.95"1.49 5.00"1.20 5.31"1.18 4.64"1.09 5.21"1.13 5.36"1.19
HDL-C, mmol/L 1.24"0.35 1.19"0.28 1.11"0.29 1.47"0.36 1.46"0.35 1.45"0.34
LDL-C, mmol/L 3.63"4.14 3.78"3.91 4.44"4.68 2.76"2.42 3.28"1.85 3.46"2.02
Triglycerides, mmol/L 1.74"1.13 1.72"2.06 1.88"1.33 1.46"1.16 1.34"0.74 1.33"0.72
ApoA1, g/L 1.45"0.27 1.39"0.26 1.32"0.26 1.62"0.33 1.59"0.31 1.59"0.28
ApoB, g/L 1.03"0.26 1.14"0.32 1.25"0.31 0.95"0.26 1.15"0.31 1.20"0.32
Age, years 45.8"17.2 44.9"15.9 46.2"16.6 43.5"15.2 45.1"16.3 43.7"15.9
´2/´2, ´2/´4 and ´4/´4 genotypes were not included in this analysis on account of their low frequencies.
The results showed a high ´3 allele frequency and
relatively low ´4 frequency, with ´2 the least common
allele.
To evaluate the importance of APOE polymor-
phisms for dyslipidemias, we compared APOE geno-
types and relative allele frequencies in normo-
lipidemic and dyslipidemic subjects stratified by sex.
In general terms we observed that genotypes with
the ´4 allele were more frequent in dyslipidemic par-
ticipants. This difference was more pronounced in
men than in women (7.1% vs. 12.0% in men; 7.6% vs.
10.4% in women).
APOE genotypes and lipids
In men, the presence of the ´2 allele was significantly
associated with a lower probability of having LDL-C
above 4.14 mmol/L (age-adjusted OR, 0.34; 95% CI,
0.15–0.75). All other associations were not statistically
significant. The presence of the ´3 allele was not
associated with either a lower or higher probability of
having any of the dyslipidemias studied.
On the other hand the presence of the ´4 allele was
significantly associated with a higher probability of
having HDL-C -1.04 mmol/L and triglycerides
G1.71 mmol/L (age-adjusted OR, 2.26; 95% CI, 1.41–
3.62), and a higher probability of having LDL-C above
4.14 mmol/L (age-adjusted OR, 1.68; 95% CI, 1.09–
2.57) and HDL-C below 1.04 mmol/L (age-adjustedOR,
1.67; 95% CI, 1.11–2.49).
In women, the presence of the ´2 allele was asso-
ciated with a significantly lower probability of having
cholesterol G5.17 and F6.18 mmol/L (age-adjusted
OR, 0.62; 95% CI, 0.39–0.99), LDL-C G3.37 and
F4.14 mmol/L (age-adjusted OR, 0.49; 95% CI, 0.27–
0.87) and LDL-C above 4.14 mmol/L (age-adjusted OR,
0.38; 95% CI, 0.19–0.78). All other associations were
not statistically significant for allele ´2. The presence
of allele ´3 was not associated with either a lower or
higher probability of having any of the dyslipidemias
studied.
The presence of the ´4 allele was significantly asso-
ciated with a higher probability of having LDL-C
above 4.14 mmol/L (age-adjusted OR, 1.79; 95% CI,
1.19–2.69) and cholesterol )6.21 mmol/L (OR, 1.85:
95% CI, 1.25–2.74). All other associations were not
statistically significant for allele ´4.
Table 3 presents mean values and standard devia-
tion for lipid parameters by sex and by the most prev-
alent APOE genotypes.
Discussion
The allelic frequencies observed in this study are in
agreement with those we obtained in another study
of the Portuguese population conducted in the Lisbon
area under the ApoEurope Project (16). As in almost
all populations, the ´3/´3 genotype was by far the
most frequent (72.4%), and the ´3 allele accounted for
the greatest majority of the APOE gene pool (84.9%)
while ´4 accounted for 9.8% and ´2 for 5.3%. As a
result of the lower frequencies of the ´4 and ´2
alleles, the genotypes ´4/´4, ´2/´4 and ´2/´2 were rel-
atively rare. We did not find significant differences in
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the distribution of the APOE alleles in the six partici-
pating regions of this study.
Worldwide APOE allele frequencies differ in various
geographic regions. In Europe the ´2 allele shows an
increasing gradient from north to south, and the
opposite is observed for the ´4 allele. The prevalence
of cardiac atherosclerotic diseases, and cholesterol
and triglyceride concentrations also show the latter
distribution. The Finnish population has the highest
prevalence of ´4 (17.8%), while the Greek (Crete)
(8.5%) and Portuguese populations (9.7%) have the
lowest prevalence (16).
In a comparative study organized by Mahley and
Rall (17) on APOE allele frequencies in 16 distinct
countries/world regions/ethnic groups, the ´2 fre-
quency ranged from 4.1% to 13% and that of ´4 from
7.4% to 29.1%. Our results are closer to regions with
the lowest frequencies of ´4 and ´2, such as Japan
and Singapore. A study in the Moroccan population
also found values rather similar to ours: ´4s11%,
´3s84%, and ´2s5% (18).
When comparing APOE genotypes and relative
allele frequencies in normo- and dyslipidemic sub-
jects, we observed that the frequency of the ´4 allele
was higher in dyslipidemic subjects of both sexes.
This was more pronounced in men due to higher fre-
quencies of the ´3/´4 and ´4/´4 genotypes than in
women, whom, on the other hand, had a low fre-
quency of the ´2 allele due to a much lower number
of ´2/´3 genotypes.
More detailed analysis of the relationship between
lipids and genotypes (Table 3) shows that genotypes
with the ´2 and ´4 alleles have respectively lower and
higher plasma cholesterol levels compared with the
´3/´3 subset.
The genotype associated with higher triglyceride
and lower HDL-C levels was ´3/´4 in men. According
to Dallongeville et al. (6), cardiovascular risk due to
the ´4 allele is increased in individuals with the ´3/´4
genotype due to elevated levels of triglycerides and
lower HDL-C concentrations – this is the characteristic
dyslipidemia of the metabolic syndrome. Moreover,
as mentioned by Assmann and co-workers, this ´3/´4
heterozygosity compared with ´3/´2 heterozygosity
and ´3/´3 homozygosity is accompanied by an earlier
age at myocardial infarction (19).
Considering the associations between lipids and
APOE alleles through the relative ORs, we can again
confirm the non-association of ´2 with cholesterol
and the association between ´2 and high triglycer-
ides/low HDL-C, as well as the association between ´4
and dyslipidemias rich in cholesterol. The numbers
expressing these ORs are relatively low, approximate-
ly 1 and 2, which is usual in this type of work wsee the
Framingham Offspring Study (7)x.
Dyslipidemias were observed in a high percentage
of the subjects studied (over 60%). This finding is rel-
evant, as dyslipidemias are an important risk factor
for atherosclerotic disorders, which in Portugal result
in high mortality and morbidity rates w39% of verified
deaths in 1999, 52% by stroke and 22% by cardiac
heart disease (12, 20)x.
Moreover the relationship that dyslipidemias have
with the pathogenesis of atherosclerosis is extensive-
ly documented and its environmental determinants
and clinical consequences are recognized (21–34).
According to this scientific evidence, Portuguese
health authorities and scientific societies have widely
and repeatedly recommended interventions for earli-
er diagnosis and control of dyslipidemias in the pop-
ulation, recognizing their importance throughout the
country (35–37).
In our study, age and sex were associated with
increased serum concentrations of the lipids and apo-
lipoproteins quantified, with the exception of HDL-C,
which was decreased.
Regarding age, the usual explanations expressed in
the literature cannot be excluded: weight gain during
adult life, heredity, selective mortality, and probably
a decrease in receptor activity (38, 39).
In relation to higher triglyceride values in men than
in women and low levels of HDL-C, either in isolation
or combined, it is possible that these reflect the influ-
ence of obesity, hypertension, a sedentary life and
other risk factors associated with metabolic syn-
drome, which are becoming increasingly prevalent in
our population, especially in men (20). The increasing
prevalence of type 2 diabetes may also be an impor-
tant cause. In fact, hyperinsulinemia is associated
with increased very low-density lipoprotein (VLDL)
secretion by the liver, decreased activity of lipoprotein
lipase and decreased HDL-C (40).
Hormonal status as a gender-specific factor could
also explain some of the lipid differences observed
between men and women. The higher cholesterol val-
ues observed in women are probably the result of
multiple effects of sex hormones on lipoprotein
metabolism. The high number of women aged over
45 years in the sample population may explain some
of the differences observed in lipid concentrations,
due to the importance of menopause.
Returning to the APOE genotypes/allelic frequen-
cies for normo- vs. dyslipidemic subjects, we
observed that ´4, the allele considered the most path-
ogenic, is more frequent in dyslipidemic than nor-
molipidemic subjects (4.9% excess in males; 2.8% in
females). In our opinion, this small excess of ´4
alleles in the dyslipidemic population studied, togeth-
er with the low OR values, suggests that ´4 is not a
major factor in explaining the occurrence of dyslipi-
demias in Portugal.
In fact, we cannot exclude the possibility that
important genetic abnormalities may be present that
influence dyslipidemias, such as familial hypercholes-
terolemia, familial defective apoB-100, and type III
hyperlipoproteinemia, although these show a low
prevalence in populations studied so far. Neverthe-
less, it is most probable that lipid variations are poly-
genic and also depend on environmental factors such
as lifestyle.
Major changes in lifestyle have taken place in Por-
tugal since the 1960s, in part associated with an inver-
sion of the age pyramid, approaching what is
observed in EU countries.
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According to the few nutrition surveys and official
aggregate statistics based on commerce and produc-
tion, during the last four decades, patterns of food
intake have changed progressively from a healthy
Mediterranean diet to an atherogenic diet, with a con-
siderable increase in the supply and use of meat,
dairy products, oils and fats (except olive oil) and add-
ed sugars (41). On the other hand, the supply of fish,
cereals and vegetables has decreased. Energy supply
from fats, which represented only approximately
24.7% of the total energy intake in the 1960s, was
34.3% of the total energy intake in the late 1990s. Ani-
mal fat intake increased from 10% to 14% of the total
energy intake during the same period (41).
It is thought that different dietary patterns in Por-
tuguese regions that may have existed in the past
have become attenuated and cannot be easily differ-
entiated today. To the best of our knowledge, only a
report from 1988 based on the 1980 national food
consumption survey identified two different nutrition-
al profiles in the country. That in the northern regions,
north from the Tejo River (Lisbon area excluded) had
traditional food intake habits, with an excess of salt
and alcoholic beverages. In the other regions, in the
south, a higher intake of proteins and animal fats and
a lower intake of carbohydrates and alcoholic bever-
ages were observed (42).
Consequently, standardized morbidity and mortali-
ty rates for nutrition-related diseases were higher in
the north (liver cirrhosis, esophageal cancer, gastric
cancer, CVD and stroke), whereas southern regions
had lower CVD, colon cancer and breast cancer rates.
Regions considered in this study included Porto,
Vila Real and Viseu in the north, where the frequency
of CVD is higher than the national average (191.7/
100,000 per year) and Lisboa, Portalegre and Faro,
where CVD is less frequent than the national average
(79.9/100,000 per year).
Other lifestyle-related risk factors deserve mention
due to their impact on the lipid profile of the popu-
lation. According to the World Drink Trends Statistics,
alcohol consumption is high in Portugal (14 L/capita
per year), clearly above the mean of EU countries. The
three available National Health Interview Surveys
show that approximately 50% of the population report
alcohol consumption. The contribution of wine, beer
and spirits is changing, with wine being more fre-
quently used by middle-aged and older people,
whereas beer and spirits are increasingly being used
by the young (43).
Portugal has the lowest smoking prevalence in
Europe. Data from the three National Health Interview
Surveys show that the prevalence of daily smoking in
men is slowly decreasing (33.3%, 29.2%, 29.3%
respectively), but increasing in women (5.0%, 6.5%,
7.9%). The increased number of female smokers is
particularly relevant in younger age groups, while the
decrease in men is observed in all age groups except
35–44 years (43).
In Portugal, as in other countries, there is a trend to
a progressive increase in the prevalence of obesity
and hypertension (44, 45).
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